Media stories about CymaBay Therapeutics (NASDAQ:CBAY) have trended somewhat positive this week, according to Accern. The research group rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CymaBay Therapeutics earned a news sentiment score of 0.19 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.9252195044809 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
CBAY has been the topic of several research reports. BidaskClub raised CymaBay Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 21st. Oppenheimer set a $15.00 price target on CymaBay Therapeutics and gave the company a “buy” rating in a research report on Wednesday, January 10th. SunTrust Banks reissued a “buy” rating and set a $19.00 price target on shares of CymaBay Therapeutics in a research report on Friday, March 16th. Zacks Investment Research lowered CymaBay Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, January 16th. Finally, HC Wainwright reissued a “buy” rating and set a $18.00 price target (up from $12.00) on shares of CymaBay Therapeutics in a research report on Wednesday, January 24th. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. CymaBay Therapeutics currently has a consensus rating of “Buy” and an average price target of $17.78.
Shares of CBAY opened at $11.10 on Friday. The firm has a market cap of $658.73, a P/E ratio of -14.05 and a beta of 2.06. The company has a quick ratio of 6.35, a current ratio of 6.35 and a debt-to-equity ratio of 0.04. CymaBay Therapeutics has a 12 month low of $3.16 and a 12 month high of $15.59.
CymaBay Therapeutics (NASDAQ:CBAY) last issued its quarterly earnings data on Thursday, March 15th. The biopharmaceutical company reported ($0.11) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.06. The company had revenue of $5.20 million for the quarter, compared to the consensus estimate of $1.25 million. equities analysts forecast that CymaBay Therapeutics will post -0.88 earnings per share for the current fiscal year.
In other news, Director Carl Goldfischer sold 15,000 shares of the stock in a transaction on Thursday, March 22nd. The stock was sold at an average price of $13.03, for a total value of $195,450.00. Following the completion of the transaction, the director now owns 9,340 shares of the company’s stock, valued at $121,700.20. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Kurt Von Emster sold 138,253 shares of the stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $10.40, for a total value of $1,437,831.20. Following the completion of the transaction, the director now directly owns 90,000 shares of the company’s stock, valued at approximately $936,000. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 815,648 shares of company stock valued at $10,283,751. 15.10% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/08/cymabay-therapeutics-cbay-receiving-somewhat-positive-press-coverage-accern-reports.html.
CymaBay Therapeutics Company Profile
Cymabay Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. It engages in developing seladelpar (MBX-8025), a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout.
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.